¹ÙÀ̰ÖÅ©¸²(Àεµ¸ÞŸ½Å)(Æ©ºê) 105g  Vigel Cream  
                    
                 
               
              
                
                     ÀϹÝÀǾàǰ | ±Þ¿©   
                        
                    	
                    
                 
               
              
                
					  
                  
				  
                 
               
              
              
              
              
                 
              
                
                    
                       
                      ¾Ë¸²:  
                      µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. 
                     
                  
 
               
            
              
                
                   
                   
                   
                   
		   
                 
               
              
                
                  
                     
                    
                       Àü¹®/ÀÏ¹Ý 
		              
                    ÀϹÝ
                       
                      
                        
                        
                          
                            
                                
                             
                           
                           
                           
                          
                          ¹é»ö ~ ¿¬ÇÑ È²»öÀÇ Å©¸²Á¦  
                          
                           
                          
			              
                            
                            
							  
							 
                             
                           
                          
                          
                            
                              
                               
                             
                           
                          
                          
                            
                            
							 
                             
                           
                          
                        
                        
                       
                     
                    
                      
					   Á¦Á¶È¸»ç 
                      
                       
                        ÃÊ´ç¾àǰ°ø¾÷(ÁÖ) 
                      
                       
                     
                    
                      
					   ÆÇ¸Åȸ»ç 
                      
                       
			            ÃÊ´ç¾àǰ°ø¾÷(ÁÖ) 
                      
                       
                     
                      
                      
                      
					   Çã°¡Á¤º¸ 
                      
                      
                                          Á¤»ó                   
                                          
                          
                                (1986.05.14) 
                           
                            
                       
                     
                    
                     
                        
	    				   BIT ¾àÈ¿ºÐ·ù 
                        
                          ¿Ü¿ë ¼Ò¿°ÁøÅëÁ¦ (NSAIDs : Skin & Mucous Membrane)
                         
                     
                    
                    
                      
					   º¹ÁöºÎºÐ·ù 
                      264[ÁøÅ롤Áø¾ç¡¤¼ö·Å¡¤¼Ò¿°Á¦                                        ] 
                     
                    
                      
					   û±¸ÄÚµå(KDÄÚµå)    ºñ±Þ¿©Á¡°ËÄÚµå 
                      
                      
                      
                        
670700376\5,557 ¿ø/105g/°³(2024.07.01) (ÇöÀç¾à°¡) \5,561 ¿ø/105g/°³(2020.09.01)(º¯°æÀü¾à°¡) 
                         
                        
						     
						     
                         
                      
                     
                       
                     
                     
                    
                       ATCÄÚµå 
                      Indometacin  / M02AA23 
                     
                    
                    
                       NDCÄÚµå 
                      
                        [Proprietary Name Search _ ƯÇãµî·Ï¸í,»óÇ¥¸íÀ¸·Î °Ë»ö]  
                        [Active Ingredient Search _ ÁÖ¼ººÐÀ¸·Î °Ë»ö]  
                        [NDC Number Search _ NDCÄÚµå·Î °Ë»ö]  
                       
                                         
                    
                      
					   ¼ººÐ / ÇÔ·®  
                      
			
			
			[½ÉÆò¿ø ÁÖ¼ººÐÄÚµå ±âÁØ ¼ººÐÇÔ·®Á¤º¸ Á¶È¸]   
			
			 
					                            
                       
                     
                        
                      
                      
					   ÷°¡Á¦ 
                      
                      
                           ±Û¸®¼¼¸° ,
                          
                           µðÀ̼ÒÇÁ·ÎÆÇ¿Ã¾Æ¹Î ,
                          
                           µðÀ̼ÒÇÁ·ÎÇʾƵðÇÁ»ê¿° ,
                          
                           ¹é´çÁö¹æ»ê¿¡½ºÅ׸£ ,
                          
                           ¿¡µ¥Æ®»ê³ªÆ®·ý¼öȹ° ,
                          
                           Á¤Á¦¼ö ,
                          
                           Ä«º¸¸Ó 934 ,
                          
                           Ä«ÇÁ¸±¸¯.Ä«ÇÁ¸¯Æ®¸®±Û¸®¼¼¸®µå ,
                          
                           Ƽ¿ÀȲ»ê³ªÆ®·ý¼öȹ° ,
                          
                           ÆÄ¶ó¿Á½Ãº¥Á¶»ê¸ÞÆ¿ ,
                          
                           ÆÄ¶ó¿Á½Ãº¥Á¶»êÇÁ·ÎÇÊ ,
                          
                          L-¸àÅç 
                                          
                       
                     
                  
                  
                 
               
            
 
            
         
      
       
   
   
  
    
      
     
     
  
                              
                                  
                                   
                               
            
            
                
            
            
              
            
                            
              
                                                     
            
            
   
  
    
      
     
   
   
     
   
    
   
    
      
        À¯·áȸ¿ø °áÀç½Ã ¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸ ¸¦
        ÀÌ¿ë ÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
        À¯·áÁ¤º¸¸ñ·Ï Àº Àü¹®È¸¿ø À¸·Î
        ·Î±×ÀÎ  ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
      
     
   
  
     
   
   
  
    
      
	
	  
	     
	    
	      
	        
            
              Çã°¡Á¤º¸ 
                         
	        
	       
	     
	     
	    
  
    Ç׸ñ 
    ³»¿ë 
   
  
   
    û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå  »óÇÑ±Ý¾× 
    
      
      
        
        670700376  
	    
	    
          [º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]   
          
        
        
        
           \5,557 ¿ø/105g/°³(2024.07.01) (ÇöÀç¾à°¡) 
            
           \5,561 ¿ø/105g/°³(2020.09.01)(º¯°æÀü¾à°¡) 
              
	 
	   
	   
       
      
       
       
     
      
      
     
      
    
    
      
     [»óº´ÄÚµåÁ¶È¸]  
      
     [Áúº´ÄÚµåÁý ´Ù¿î·Îµå]  
     [¿ì¸®Áý°Ç°ÁÖÄ¡ÀÇ ¹Ù·Î°¡±â]  
     
   
   
    ºü¸¥Á¶È¸ 
    
      
       
   
  
  
   
    Á¦Ç°¼º»ó 
    
      ¹é»ö ~ ¿¬ÇÑ È²»öÀÇ Å©¸²Á¦  
      
	    [Á¦ÇüÁ¤º¸ È®ÀÎ]  
       
   
  
  
  
  
  
   
    Æ÷À塤À¯Åë´ÜÀ§ 
    105g/Æ©ºê 
   
  
  
  
   
    Æ÷À塤ÄÚµå´ÜÀ§ 
    
        
        
            ¾àǰ±Ô°Ý  
            ´ÜÀ§  
            ´ëÇ¥ÄÚµå  
            Ç¥ÁØÄÚµå  
            ºñ°í  
	     
        
        
            105±×·¥ 
            1 °³ 
            8806707003700 
            8806707003762 
             
	     
        
        
     
   
      
  
  	
   
    ÁÖ¼ººÐÄÚµå 
    
      174834CCM  
      
	  [µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]  
     
   
  
  
  
  
  	
   
    ´ëÇ¥ÄÚµå 
    8806707003700 
   
  
  
  
  
   
    º¸°ü¹æ¹ý 
    ±â¹Ð¿ë±â 
   
  
  
  
   
    ¾à¸®ÀÛ¿ë 
    
      
        [Á¶È¸]  
     
      
  
  
  
  
   
    È¿´ÉÈ¿°ú 
     
    [ÀûÀÀÁõ º° °Ë»ö]   
      
    
     
	 
      ´ÙÀ½ Áúȯ ¹× Áõ»óÀÇ ÁøÅë¤ý¼Ò¿° : ÅðÇ༺°üÀý¿°(°ñ°üÀý¿°), ¾î±ú°üÀýÁÖÀ§¿°, °Ç¤ý°ÇÃÊ¿°, °ÇÁÖÀ§¿°, »ó¿Ï°ñ»ó°ú¿°(Å״Ͻº ¿¤º¸¿ì µî), ±ÙÀ°Åë, ¿Ü»óÈÄÀÇ Á¾Ã¢¤ýµ¿Åë 
      
      
      
      
     
   
  
  
  
  
  
  
  
  
    
  
  
   
    ¿ë¹ý¿ë·® 
     
      * Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.  
    
     
      
      
    [󹿾à¾î]  
      Áõ»ó¿¡ µû¶ó Àû´ç·®À» 1ÀÏ ¼öȸ ȯºÎ¿¡ ¹Ù¸£°í Àß ½º¸çµéµµ·Ï °¡º±°Ô ¹®Áö¸¥´Ù.      
      	    
     
   
  
  
  
   
    ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë 
    
        
	  [º¸±â]  
     
   
  
  
  
  
  
  
  
   
    ±Ý±â 
     
      1) ÀÌ ¾à ¶Ç´Â ±âŸÀÇ Àεµ¸ÞŸ½Å Á¦Á¦¿¡ °ú¹ÎÁõ ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ 
2) ¾Æ½ºÇǸ° õ½Ä(ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°ÁøÅëÁ¦ µî¿¡ ÀÇÇÑ Ãµ½Ä¹ßÀÛ À¯¹ß) ¶Ç´Â ±× º´·ÂÀÌ Àִ ȯÀÚ(ÁßÁõ õ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù) 
3) ¾Æ½ºÇǸ° ¶Ç´Â ±âŸÀÇ ºñ½ºÅ×·ÎÀ̵强 ¼Ò¿°ÁøÅëÁ¦¿¡ ±â°üÁö°æ·ÃÀÇ º´·Â, ºñ¿° ¹× ¸Æ°üºÎÁ¾À» ÀÏÀ¸Å² ȯÀÚ 
4) 14¼¼ ¹Ì¸¸ÀÇ ¼Ò¾Æ 
     
   
  
  
  
  
   
    ½ÅÁßÅõ¿© 
     ±â°üÁö õ½Ä ȯÀÚ(ÁßÁõ õ½Ä¹ßÀÛÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù) 
   
  
  
  
   
    ÀÌ»ó¹ÝÀÀ 
     
      1) ¶§¶§·Î °¡·Á¿ò, ¹ßÀû, ¹ßÁø, Á¢ÃËÇǺο°, ½ÀÁø(Åõ¿© ÁßÁö½Ã Áõ»óÀÌ ¼Ò½ÇµÈ´Ù)ÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¸ç µå¹°°Ô ¿°¨, Á¾Ã¢, È«Á¶, ¾Æ³ªÇʶô½Ã, ±¤°ú¹ÎÁõ, ÀÛ¿°¨, Àڱذ¨, °ÇÁ¶°¨ ¹× Àú¸°°¨, À§Àå°üºÒÄè°¨, µÎÅë, ¾îÁö·¯¿òÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ÀÌ·¯ÇÑ Áõ»óÀÌ ½ÉÇÑ °æ¿ì¿¡´Â »ç¿ëÀ» ÁßÁöÇÑ´Ù. 
2) °Ç¼± ȯÀÚÀÇ °æ¿ì Áõ»óÀÌ ¾Ç鵃 ¼ö ÀÖ´Ù. 
3) ÇǺιÝÀÀ, ±â°üÁö°æ·Ã, ¼ï¿¡ À̸£´Â Ç÷¾ÐÇϰ µîÀÇ °ú¹Î ¹ÝÀÀÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. Ư¼öÇÑ °æ¿ì µÎÅë, ±¸¿ª, ±¸Åä, ¿, µÞ¸ñ »»»»ÇÔ ¶Ç´Â ÀǽÄȥŹ µîÀÇ Áõ»óÀ» ¼ö¹ÝÇÏ´Â ¹«±Õ¼º ³ú¸·¿°ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
4) ¿ë¾× ÈíÀԽà ±âµµÀÚ±ØÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù(½ºÇÁ·¹À̾×Á¦¿¡ ÇÑÇÔ). 
          
     
   
  
  
    
   
    ÀϹÝÀû ÁÖÀÇ 
     1) ¼Ò¿° ÁøÅëÁ¦¿¡ ÀÇÇÑ Ä¡·á´Â ¿øÀοä¹ýÀÌ ¾Æ´Ñ ´ëÁõ¿ä¹ýÀÓ¿¡ À¯ÀÇÇÑ´Ù. 
2) ÇǺÎÀÇ °¨¿°ÁõÀ» ºÒÇö¼ºÈ ½Ãų ¼ö ÀÖÀ¸¹Ç·Î °¨¿°À» ¼ö¹ÝÇÏ´Â ¿°Áõ¿¡ ´ëÇØ ÀÌ ¾àÀ» »ç¿ëÇÏ´Â °æ¿ì¿¡´Â Àû´çÇÑ Ç×±ÕÁ¦ ¶Ç´Â Ç×Áø±ÕÁ¦¸¦ º´¿ëÇϰí ÃæºÐÈ÷ °üÂûÇÏ¿© ½ÅÁßÈ÷ Åõ¿©ÇÑ´Ù. 
3) ¸¸¼ºÁúȯ(ÅðÇ༺°üÀý¿°(°ñ°üÀý¿°) µî)¿¡ ÀÌ ¾àÀ» »ç¿ëÇÏ´Â °æ¿ì¿¡´Â ¾à¹°¿ä¹ý ÀÌ¿ÜÀÇ ¿ä¹ýµµ °í·ÁÇÑ´Ù. ¶Ç ȯÀÚ »óŸ¦ ÃæºÐÈ÷ °üÂûÇÏ¿© ºÎÀÛ¿ë ¹ßÇö¿¡ À¯ÀÇÇÑ´Ù. 
4) ±ÇÀå¿ë·®À» ÃʰúÇÏ¿© Àå±â°£ ³ÐÀº ºÎÀ§¿¡ ¹Ù¸¦ °æ¿ì Àü½ÅºÎÀÛ¿ëÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù. 
5) ¼ö¼ú ÈÄ¿¡ »ý±ä »óó¿¡ ¹Ù¸¥ ÈÄ °ú¹Î¼º ¼ïÀÌ ³ªÅ¸³µ´Ù´Â º¸°í°¡ ÀÖ´Ù. 
6) ÀÌ ¾àÀº ¾È½ÄÇâ»ê(³ªÆ®·ý)À» Æ÷ÇÔÇϰí ÀÖ¾î ÇǺÎ, ´«, Á¡¸·¿¡ °æ¹ÌÇÑ ÀÚ±ØÀÌ µÉ ¼ö ÀÖ´Ù. 
 
   
  
  
  
    
   
    »óÈ£ÀÛ¿ë 
     °ú·®Åõ¿©½Ã Äí¸¶¸°, Ç÷´ç°ÇÏÁ¦, Ƽ·Ï½Å°ú »óÈ£ÀÛ¿ëÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÁÖÀÇÇÑ´Ù. 
   
  
  
  
   
    ÀӺο¡ ´ëÇÑ Åõ¿© 
     
      
	[ÀӺαݱ⠼ººÐ Á¶È¸]         
      1) ÀӽŠ3±â : ÇÁ·Î½ºÅ¸±Û¶õµò ÇÕ¼ºÀúÇØ·Î ÀÎÇØ Ãâ»êÀÌ Áö¿¬µÉ ¼ö ÀÖÀ¸¸ç Ãâ»ê½Ã ½ÇÇ÷, ½Å»ý¾Æ ÃâÇ÷, žÆÀÇ ½ÉÆóµ¶¼º(µ¿¸Æ°ü Á¶±âÆó¼â¸¦ ¼ö¹ÝÇÏ´Â Æó°íÇ÷¾Ð), ½Å±â´ÉÀúÇÏ·Î ¾ç¼ö°ú¼ÒÁõÀ» ¼ö¹ÝÇÏ´Â ½ÅºÎÀü µîÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ ½Ã±âÀÇ ÀӺο¡´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù. 
2) ÀӽŠ1±â ¹× 2±â : µ¿¹°ÀÇ »ý½Ä½ÇÇè °á°ú ÅÂÀÚµ¶¼ºÀº ¹ß»ýÇÏÁö ¾Ê¾ÒÀ¸³ª ÀӺο¡ ´ëÇÑ ¿¬±¸´Â ¾ÆÁ÷ ¹àÇôÁø ¹Ù ¾ø´Ù.
 
     
   
  
  
  
  
   
    ¼öÀ¯ºÎ¿¡ ´ëÇÑ Åõ¿© 
     ¿µ¾Æ¿¡ ´ëÇÑ À§ÇØ¿©ºÎ´Â ¾ÆÁ÷ ¹àÇôÁø ¹Ù ¾øÀ¸³ª ÀÌ ¾àÀÌ ¸ðÀ¯·Î ÀÌÇàÇϹǷΠ¼öÀ¯ºÎ¿¡´Â »ç¿ëÇÏÁö ¾Ê´Â´Ù. 
   
  
  
  
  
   
    ¼Ò¾Æ¿¡ ´ëÇÑ Åõ¿© 
     
      
       
      ¼Ò¾Æ¿¡ ´ëÇÑ ¾ÈÀü¼ºÀÌ È®¸³µÇ¾î ÀÖÁö ¾Ê´Ù. 
   
  
  
  
  
  
  
  
  
  
  
  
    
   
    Àû¿ë»óÀÇ ÁÖÀÇ 
     1) º´º¯ÀÌ ÀÖ´Â ÇǺÎ(ÃâÇ÷¼º ÇǺÎÁúȯ, ½ÀÁø, °¨¿°µÈ º´º¯, È»ó, »óó), ´« ¹× Á¡¸·¿¡ »ç¿ëÇÏÁö ¾Ê´Â´Ù. 
2) ÇǺο¡ ¼Õ»óÀÌ ÀÖÀ» °æ¿ì »ç¿ëÇϸé ÀϽÃÀûÀÎ ÀÚ±Ø ¹× Àú¸°°¨À» ÀÏÀ¸Å³ ¼ö ÀÖÀ¸¹Ç·Î »ç¿ë½Ã ÁÖÀÇÇÑ´Ù. 
3) ¿Ü¿ëÀ¸·Î¸¸ »ç¿ëÇÑ´Ù. 
4) ¹ÐºÀºØ´ë¹ýÀ¸·Î »ç¿ëÇÏÁö ¾Ê´Â´Ù. 
 
   
  
  
  
   
    °ú·®Åõ¿© ¹× óġ 
     1) Áõ»ó 
ÀÌ ¾àÀÇ °ú·®º¹¿ë½Ã ±¸¿ª, ±¸Åä, º¹ºÎÆØ¸¸°¨, À̱ÞÈÄÁß, ¼³»ç, À§Àå°ü ÃâÇ÷ µîÀÇ À§Àå°ü Áõ»ó ¹× ÁßÁõ µÎÅë, ¾îÁö·¯¿ò, Âø¶õ, ¹æÇâ»ó½Ç, ±â¸é, ºÒ¸é, ÇÇ·Î, ºÒ¾È, ½Ã°¢Àå¾Ö, °¨°¢ÀÌ»ó, ¹«°¨°¢, °æ·Ã µîÀÇ Àü½Å ºÎÀÛ¿ëÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. ¶ÇÇÑ ÀúÇ÷¾Ð, È£Èí°ï¶õ ¹× û»öÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. 
2) óġ 
(1) ÀÌ Ã³Ä¡¹ýÀº ´ëÁõÀû º¸Á¶¿ä¹ýÀÌ´Ù. Åõ¿© ÈÄ ½Ã°£ÀÌ ¿À·¡ °æ°úÇÏÁö ¾ÊÀº °æ¿ì À§¼¼Ã´À» ÇÑ´Ù. ÀÚ¿¬ ±¸Åä°¡ µÇÁö ¾ÊÀº °æ¿ì ±¸ÅäÀ¯¹ßÁ¦¸¦ ÀÌ¿ëÇϸç ÀÌ¿Í °°Àº Á¶Ä¡°¡ ºÎÀû´çÇÑ È¯ÀÚÀÇ °æ¿ì À§¼¼Ã´À» ½Ç½ÃÇÑ´Ù. À§¸¦ ºñ¿î ÈÄ 25 - 50mgÀÇ È°¼ºÅºÀ» Åõ¿©ÇÑ´Ù. ÇÊ¿äÇÑ °æ¿ì Ç÷ûÀüÇØÁú´ëü¹æ¹ýÀ» »ç¿ëÇÑ´Ù. 
(2) ±âº»ÀûÀ¸·Î ¹°-ÀüÇØÁúÀÇ ±ÕÇüÀ» °Ë»çÇÏ¿© Á¶ÀýÇÏ¿©¾ß Çϸç ȯÀÚÀÇ »óÅ¿¡ µû¶ó öÀúÇÑ ÀÇÇÐÀû °üÂû ¹× À¯Áö¿ä¹ýÀÌ ÇÊ¿äÇÒ ¼ö ÀÖ´Ù. 
(3) ÀÌ ¾àÀÇ ºÎÀÛ¿ëÀ¸·Î ÀÎÇÑ À§Àå°ü ±Ë¾ç°ú ÃâÇ÷ÀÇ À§ÇèÀÌ ÀÖÀ¸¹Ç·Î ¼öÀϰ£ ¸ð´ÏÅ͸µ ÇØ¾ßÇÑ´Ù. Á¦»êÁ¦¸¦ »ç¿ëÇÏ¿© Áõ»óÀ» ¿ÏȽÃų ¼ö ÀÖ´Ù. 
 
   
  
  
  
  		
  
  
   
    º¸°ü ¹× Ãë±Þ»óÀÇ ÁÖÀÇ 
    ±â¹Ð¿ë±â 
   
  	
  
  
  
  
  
  
   
    Related FDA Approved Drug 
    
       
     
      
  
  
      							
 
	  
	 
	
	  
       
	    
	      
	        
            
              Á¤º¸¿ä¾à 
                 
	        
	       
	           	    
	     
	    
  
    µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸ 
    
  
  
    
  
    
	  
	 
	
	  
       
	    
	      
	        
            
              ÄÚµå ¹× ºÐ·ùÁ¤º¸ 
                 
	        
	       
	           	    
	     
	    	  
	  
	 
	
	  
       
	    
	      
	        
            
              Á¦Ç°Á¤º¸ 
                             
	        
	       
	           	  
	     
	     
	  
	 
	
	  
       
	    
	      
	        
            
              º¹¾àÁ¤º¸ 
                             
	        
	       
	           	  
	     
	    
  
    Ç׸ñ 
    ³»¿ë 
   
   
    LACTmed ¹Ù·Î°¡±â 
    
      
        [¹Ù·Î°¡±â]  
     
     
  
  
   
    ¾à¸®ÀÛ¿ë 
    
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù. 
       
     
     
  
  
  
   
    Ãà¾àº¹¾àÁöµµ 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù. 
    
     
   
       
  
  
   
    º¹¾àÁöµµ 
    
     
    À¯·áÁ¤º¸ÀÔ´Ï´Ù. 
    
     
   
                                                          															
  
   
  
  
   
    ÀӺο¡´ëÇÑÅõ¿© 
    
      
      
        
	      
	      
	        *   
	        
	          ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù. 
	          
	         
	      
	       
	   
	  
	      
	   
	  
	    
	     FDA : Dµî±Þ 
				        
				         (ÀӽŠ3±â¿¡ Åõ¿©½Ã )
				        
	   
	  
	  
	  
	     
	     
	     
	     
	     
	     
	   
	 
	
	  
	      
	      
	        *   
	        
	          »ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. 
	         
	         
	      
	        *   
	        
	          ¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í  ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù. 
	         
	         
	      
	   
	 
      
     
   
  
  
  	   
  
  	   
  
  	   
  
  
     
      Pharmacokinetics 
      
       
      À¯·áÁ¤º¸ÀÔ´Ï´Ù. 
      
         
     
  
  
  
  
  
  
  	
  
  
  	
  
  
   
    Á¦Çüº° º¹¾àÁöµµ 
    [Å©¸²]  
   
  
  
   
    º¸°ü»ó ÁÖÀÇ 
    
      
    	
     
   
  
  
   
    Á¶Á¦½Ã ÁÖÀÇ 
    
      
    	
     
      
 
	  
	 
	
	  
       
	    
	      
	        
            
              ½É»çÁ¤º¸ 
                             
	        
	       
	           	  
	     
	     
	  
	   
	
	  
       
	    
	      
	        
            
              ÇмúÁ¤º¸ 
                             
	        
	       
	           	  
	     
	    
  
    Ç׸ñ 
    ³»¿ë 
   
  
    DUR (ÀǾàǰ»ç¿ëÆò°¡) 
    º´¿ë±Ý±â :
     
	 °í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
	 
	 [»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]  										
	  ¿¬·É´ë±Ý±â :
      °í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
      
      [¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]  
       
       
        
        
     
   
  
   
    µ¶¼ºÁ¤º¸ 
    Indomethacin ¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸  : Á¤º¸º¸±â  
  Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do  
   
  
   
    Mechanism of Action 
    
      Indomethacin¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸  Antiinflammatory effects of Indomethacin are believed to be due to inhibition of cylooxygenase in platelets which leads to the blockage of prostaglandin synthesis. Antipyretic effects may be due to action on the hypothalamus, resulting in an increased peripheral blood flow, vasodilation, and subsequent heat dissipation. 
     
   
  
   
    Pharmacology 
     
      Indomethacin¿¡ ´ëÇÑ Pharmacology Á¤º¸  Indomethacin, a nonsteroidal antiinflammatory drug (NSAID) with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain. 
     
   
  
   
    Metabolism 
    
      Indomethacin¿¡ ´ëÇÑ Metabolism Á¤º¸  # Phase_1_Metabolizing_Enzyme:Cytochrome P450 2C19 (CYP2C19)UDP-glucuronosyltransferase 1-9 (UGT1A9) 
     
   
  
   
    Absorption 
    
      Indomethacin¿¡ ´ëÇÑ Absorption Á¤º¸  Bioavailability is approximately 100% following oral administration and 80??0% following rectal administration. 
     
   
  
   
    Pharmacokinetics 
    
      IndomethacinÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á  
ÀÛ¿ë¹ßÇö½Ã°£ : 30ºÐ À̳» 
 ÀÛ¿ëÁö¼Ó½Ã°£ : 4-6 ½Ã°£ 
 Èí¼ö : ½Å¼ÓÇϰÔ, ¸¹Àº ¾çÀÌ Èí¼öµÊ 
 ºÐÆ÷ : ºÐÆ÷¿ëÀû : 0.34-1.57 L/kg.  ÅÂ¹Ý Åë°ú, À¯Áó ºÐºñ 
 ´Ü¹é°áÇÕ : 90% 
 ´ë»ç : °£´ë»ç, Àå°£¼øÈ¯ 
 ¹Ý°¨±â : 4.5 ½Ã°£.  ½Å»ý¾Æ¿¡¼´Â ¿¬ÀåµÊ 
 Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : °æ±¸ : 3-4 ½Ã°£ À̳» 
 ¼Ò½Ç : Àå°£¼øÈ¯ Å.  ÁÖ·Î glucuronide Æ÷ÇÕü·Î¼ ½Å¹è¼³  
     
   
  
   
    Toxicity 
    
      Indomethacin¿¡ ´ëÇÑ Toxicity Á¤º¸  The following symptoms may be observed following overdosage: nausea, vomiting, intense headache, dizziness, mental confusion, disorientation, or lethargy. There have been reports of paresthesias, numbness, and convulsions. The oral LD50  of indomethacin in mice and rats (based on 14 day mortality response) was 50 and 12 mg/kg, respectively. 
     
   
  
   
    Drug Interactions 
    
      Indomethacin¿¡ ´ëÇÑ Drug_Interactions Á¤º¸  Acebutolol	Risk of inhibition of renal prostaglandinsAtenolol	Risk of inhibition of renal prostaglandinsBetaxolol	Risk of inhibition of renal prostaglandinsBevantolol	Risk of inhibition of renal prostaglandinsBisoprolol	Risk of inhibition of renal prostaglandinsCarteolol	Risk of inhibition of renal prostaglandinsCarvedilol	Risk of inhibition of renal prostaglandinsMethotrexate	The NSAID increases the effect and toxicity of methotrexateDiflunisal	Diflunisal increases the effect and toxicity of indomethacinEsmolol	Risk of inhibition of renal prostaglandinsLabetalol	Risk of inhibition of renal prostaglandinsMetoprolol	Risk of inhibition of renal prostaglandinsNadolol	Risk of inhibition of renal prostaglandinsLosartan	Indomethacin decreases the effect of losartanLithium	The NSAID increases serum levels of lithiumOxprenolol	Risk of inhibition of renal prostaglandinsPenbutolol	Risk of inhibition of renal prostaglandinsPindolol	Risk of inhibition of renal prostaglandinsPractolol	Risk of inhibition of renal prostaglandinsProbenecid	Probenecid increases the effect/toxicity of indomethacinSotalol	Risk of inhibition of renal prostaglandinsPropranolol	Risk of inhibition of renal prostaglandinsTimolol	Risk of inhibition of renal prostaglandinsWarfarin	The NSAID increases the anticoagulant effectAcenocoumarol	The NSAID increases the anticoagulant effectDicumarol	The NSAID increases the anticoagulant effectAnisindione	The NSAID increases the anticoagulant effectTorasemide	The NSAID decreases the diuretic and antihypertensive effects of the loop diureticBumetanide	The NSAID decreases the diuretic and antihypertensive effects of the loop diureticFurosemide	The NSAID decreases the diuretic and antihypertensive effects of the loop diureticEthacrynic acid	The NSAID decreases the diuretic and antihypertensive effects of the loop diureticCyclosporine	Monitor for nephrotoxicityAlendronate	Increased risk of gastric toxicityTriamterene	Risk of acute renal impairment with this combination 
     
   
  
   
    CYP450  Drug Interaction 
    
      [CYP450 TableÁ÷Á¢Á¶È¸]  
     
   
  
   
    Food Interaction 
    
      Indomethacin¿¡ ´ëÇÑ Food Interaction Á¤º¸  Avoid alcohol.Take with food or antacids to reduce irritation. 
     
   
  
   
    Drug Target 
    
      
      [Drug Target]  
     
   
  
   
    Description 
    
      Indomethacin¿¡ ´ëÇÑ Description Á¤º¸  A non-steroidal anti-inflammatory agent (NSAID) that inhibits the enzyme cyclooxygenase necessary for the formation of prostaglandins and other autacoids. It also inhibits the motility of polymorphonuclear leukocytes. [PubChem] 
     
   
  
   
    Dosage Form 
    
      Indomethacin¿¡ ´ëÇÑ Dosage_Form Á¤º¸  Capsule	OralPowder, for solution	IntravenousSuppository	Rectal 
     
   
  
   
    Drug Category 
    
      Indomethacin¿¡ ´ëÇÑ Drug_Category Á¤º¸  Anti-Inflammatory Agents, Non-SteroidalAnti-inflammatory AgentsCardiovascular AgentsCyclooxygenase InhibitorsGout SuppressantsNonsteroidal Antiinflammatory Agents (NSAIDs)Tocolytic Agents 
     
   
  
   
    Smiles String Canonical 
    
      Indomethacin¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸  COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O 
     
   
  
   
    Smiles String Isomeric 
    
      Indomethacin¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸  COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O 
     
   
  
   
    InChI Identifier 
    
      Indomethacin¿¡ ´ëÇÑ InChI_Identifier Á¤º¸  InChI=1/C19H16ClNO4/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12/h3-9H,10H2,1-2H3,(H,22,23)/f/h22H 
     
   
  
   
    Chemical IUPAC Name 
    
      Indomethacin¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸  2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic acid 
     
   
  
   
    Drug-Induced Toxicity Related Proteins 
    
      INDOMETHACIN   ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸Replated Protein  :Tumor necrosis factor receptor superfamily member 1A (TNF-R1)Drug  :indomethacin Toxicity  :gastric damage and granulocyte infiltration. [¹Ù·Î°¡±â] Replated Protein  :Plasma kallikrein Drug  :indomethacin Toxicity  :enterocolitis. [¹Ù·Î°¡±â] Replated Protein  :Heat shock 70 kDa proteinDrug  :indomethacin Toxicity  :denatured proteins. [¹Ù·Î°¡±â] Replated Protein  :c-myc oncogeneDrug  :indomethacin Toxicity  :apoptosis by indomethacin. [¹Ù·Î°¡±â] Replated Protein  :Acetylcholinesterase Drug  :indomethacin Toxicity  :enhance contractility of the small intestine. [¹Ù·Î°¡±â] Replated Protein  :G1/S-specific cyclin-D1Drug  :indomethacin Toxicity  :arrests endothelial cell proliferation. [¹Ù·Î°¡±â] Replated Protein  :Acetylcholinesterase Drug  :indomethacin Toxicity  :enhance contractility of the small intestine. [¹Ù·Î°¡±â] Replated Protein  :P-selectin Drug  :indomethacin Toxicity  :Indomethacin induced gastropathy. [¹Ù·Î°¡±â] Replated Protein  :B2 bradykinin receptorDrug  :indomethacin Toxicity  :enterocolitis. [¹Ù·Î°¡±â] Replated Protein  :Nitric oxide synthase, inducible Drug  :indomethacin Toxicity  :gastric damage and granulocyte infiltration. [¹Ù·Î°¡±â] Replated Protein  :Intercellular adhesion molecule 1 Drug  :indomethacin Toxicity  :Indomethacin induced gastropathy. [¹Ù·Î°¡±â] Replated Protein  :Plasma kallikrein Drug  :indomethacin Toxicity  :enterocolitis. [¹Ù·Î°¡±â] Replated Protein  :Integrin alpha-M Drug  :indomethacin Toxicity  :experimental dystonia. [¹Ù·Î°¡±â] Replated Protein  :Tumor necrosis factor Drug  :indomethacin Toxicity  :gastric damage and granulocyte infiltration. [¹Ù·Î°¡±â] Replated Protein  :Cytochrome b5Drug  :indomethacin  Toxicity  :selective effect of a p-chlorophenyl moiety. [¹Ù·Î°¡±â] Replated Protein  :NADH-cytochrome b5 reductaseDrug  :indomethacin  Toxicity  :selective effect of a p-chlorophenyl moiety. [¹Ù·Î°¡±â] Replated Protein  :Epoxide hydrolaseDrug  :indomethacin  Toxicity  :selective effect of a p-chlorophenyl moiety. [¹Ù·Î°¡±â]  
     
   
    
 
	  
	   
	
	  
       
	    
	      
	        
            
              »ç¿ëÀÚÄÁÅÙÃ÷ 
                             
	        
	       
	           	  
       
	     
	  
	     	
 
  
   
   
     
   
  
    
      
        
          
            
              
                ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-12-09
               
              
                
                º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
                 
                   
             
                         
      
           
          
                
                    
                       ¾Ë¸² 
                       
                      »ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù.  
                    
                  
 
               
      
      
                
                    
                       °æ°í 
                     
                      µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù. 
                          Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â 
                          Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡± ¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
                            ¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù. 
                          ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
 
                    
                  
 
               
  
  
    ¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é 
    ¿©±â ·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
  
  
 
  º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ